Opendata, web and dolomites

RESHAPE SIGNED

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESHAPE project word cloud

Explore the words cloud of the RESHAPE project. It provides you a very rough idea of what is the project "RESHAPE" about.

tissue    fih    supports    regulatory    imbalance    inflammation    care    therapy    trials    organ    therapeutic    treg    generation    antigen    economic    combat    curative    transfer    treatment    clinical    gene    limitations    proven    backgrounds    models    performed    limited    allografts    longtrack    immunity    tested    atmp    suffering    transform    pioneers    translation    biotech    functional    cells    function    specificity    enhanced    encouraging    technologies    vivo    changer    transplant    rejection    host    preclinical    biomarker    allotransplantation    ec    versus    cell    triple    game    recipient    human    data    entities    transplantation    science    hematopoietic    undesired    academic    medicine    overcome    broad    overcoming    members    diseases    first    cas9    record    disease    health    options    adoptive    stability    transdisciplinarity    graft    platforms    1st    hsc    studies    accompanied    presently    vitro    patients    reaction    crispr    conditioning    stem    medicinal    immune    reshape    regenerative    basic    option   

Project "RESHAPE" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 13˙137˙396 €
 EC max contribution 13˙137˙396 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 4˙137˙775.00
2    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) participant 2˙023˙468.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙998˙550.00
4    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 1˙548˙050.00
5    TISSUSE GMBH DE (BERLIN) participant 1˙026˙250.00
6    CELL THERAPY CATAPULT LIMITED UK (LONDON) participant 975˙625.00
7    TXCELL FR (VALBONNE) participant 502˙077.00
8    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 499˙500.00
9    INNOVATION ACTA S.R.L. IT (ROMA) participant 426˙100.00

Map

 Project objective

Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy. Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments. Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation. Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESHAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESHAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More